Sorafenib for the treatment of hepatocellular carcinoma

ǂa ǂsingle-centre real-world study

Jurij Hanžel (Author), Tajda Božič (Author), Borut Štabuc (Author), Rado Janša (Author)

Abstract

Background Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma. Its efficacy in randomised controlled trials was demonstrated in patients with well-preserved liver function and good functional status. In the real-world setting, treatment is often offered to patients outside these criteria. We therefore performed a single-centre real-world cohort study on the efficacy of sorafenib in patients with hepatocellular carcinoma. Patients and methods We identified all patients with hepatocellular carcinoma initiating treatment with sorafenib between January 2015 and January 2018. The primary endpoint was overall survival (OS) since starting sorafenib. Clinical and demographic variables associated with survival were studied. Results The median OS was 13.4 months (95% CI 8.2%18.6). Multivariable Cox%s regression identified worse ECOG performance status (HR 2.21; 95% CI 1.56%3.16; P < 0.0001), Child-Pugh class C (HR 52.4; 95% CI 3.20%859; P = 0.005) and absence of prior locoregional treatment (HR 2.30; 95% CI 1.37%3.86; P = 0.002) to be associated with increased mortality. Conclusions Careful selection of patients for treatment with sorafenib is of paramount importance to optimize outcomes.

Keywords

hepatocellular carcinoma;survival;sorafenib;

Data

Language:	English
Year of publishing:	2020
Typology:	1.01 - Original Scientific Article
Organization:	OI - Institute of Oncology
Publisher:	Association of Radiology and Oncology
UDC:	616-006
COBISS:	19073283
ISSN:	1318-2099
Views:	22
Downloads:	17
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	Slovenian
Secondary keywords:	hepatocelularni karcinom;preživetje;sorafenib;
Source comment:	Soavtorji: Tajda Kosir Bozic, Borut Stabuc, Rado Jansa;
Pages:	str. 233-236, XI
Volume:	ǂVol. ǂ54
Issue:	ǂno. ǂ2
Chronology:	Jun. 2020
DOI:	10.2478/raon-2020-0027
ID:	24512692